BRONCHIOLITIS OBLITERANS SYNDROME
Clinical trials for BRONCHIOLITIS OBLITERANS SYNDROME explained in plain language.
Never miss a new study
Get alerted when new BRONCHIOLITIS OBLITERANS SYNDROME trials appear
Sign up with your email to follow new studies for BRONCHIOLITIS OBLITERANS SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Inhaled drug aims to save transplanted lungs from silent threat
Disease control TerminatedThis study tested an inhaled form of cyclosporine A (L-CsA) added to standard care for lung transplant patients with bronchiolitis obliterans syndrome (BOS), a condition that scars the lungs' small airways. The goal was to see if the treatment could slow the decline in lung funct…
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug itacitinib tested for lung transplant complication – study stopped early
Disease control TerminatedThis early-phase trial tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of chronic lung rejection) after a double lung transplant. The goal was to see if itacitinib could safely improve lung function. However, the study was terminate…
Matched conditions: BRONCHIOLITIS OBLITERANS SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC